FDAnews Drug Daily Bulletin

JERINI REPORTS INCREASE IN REVENUES FOR THIRD QUARTER AND FOR THE FIRST NINE MONTHS

Dec. 2, 2005
A A

The Berlin-based pharmaceutical company Jerini AG (FSE:JI4) reported a 47 percent increase in its third quarter revenues to EUR 2.5 million from EUR 1.7 for the same period in 2004. The G&A expense increased to EUR 2.4 million compared to EUR 0.8 million as a result of the expansion in the investor relations and marketing departments. The loss from operations (EBIT) in the third quarter amounted to (EUR 4.2 million) compared to (EUR 3.0 million) for the third quarter 2004.
Biotech Intelligence